4598.T
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
Business. The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development and commercialization of prescription drugs and therapies.
The company's capital structure is characterized by a strong liquidity position, with cash and equivalents amounting to ¥338.8 million, which significantly exceeds its total liabilities of ¥156.5 million. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 2.52 suggests the company has sufficient short-term assets to cover its short-term liabilities.
Profitability metrics show a challenging performance, with a negative return on equity of -6.1958 and a return on assets of -3.9628. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating and net losses of ¥1.7 billion each further underscore the company's current financial difficulties.
The company's revenue is not disclosed in the provided data, and no specific segments or geographic regions are detailed. However, the absence of segment or geographic breakdown suggests that the company may have a concentrated business model, which could expose it to higher risk if a particular product or market underperforms.
The company's growth trajectory is currently negative, with operating and net losses in the most recent period. There is no indication of a recovery in the near term, and the company's free cash flow is negative at ¥1.7 billion. This suggests that the company is not generating sufficient cash from operations to fund its activities and may need to rely on external financing or asset sales to continue operations.
Risk factors include the company's negative profitability and liquidity risk, as it is not generating positive cash flows from operations. The company has no immediate filing-based liquidity or dilution flags, and the dilution potential is assessed as low. However, the company's reliance on cash reserves to fund operations could become a concern if the negative cash flow persists.
Recent events include the most recent financial filing, which shows continued losses and negative cash flows. No specific events such as new product launches, regulatory approvals, or strategic partnerships are disclosed in the provided data. The company's financial performance and cash flow position suggest a need for strategic action to address its current challenges.
- The company has a strong liquidity position with no long-term debt and a current ratio of 2.52.
- The company is currently unprofitable, with negative returns on equity and assets.
- The company's financial performance is deteriorating, with significant operating and net losses.
- The company has no immediate liquidity or dilution risks, but its negative cash flows could become a concern.
- The company's business model appears to be concentrated, with no disclosed segments or geographic diversification.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 4598.T Market data — financials · 2026-05-26